Shows / TheBrief.Health
Episodes
- TheBrief.Health
Adjuvant CDK4/6 Benefits Diverge in Early Breast Cancer
A 2026 meta-analysis found abemaciclib and ribociclib improved invasive disease-free survival in early HR-positive, HER2-negative breast cancer, unlike…
- TheBrief.Health
Adjuvant CDK4/6 Benefits Diverge in Early Breast Cancer
A 2026 meta-analysis found adjuvant abemaciclib and ribociclib improved invasive disease-free survival, while palbociclib did not, reinforcing drug-specific…
- TheBrief.Health
Sickle Cell Anemia Guidance Expands Hydroxyurea Access
WHO recommends universal hydroxyurea treatment for children with sickle cell anemia from 9 months through age 19, emphasizing early care and stronger…
- TheBrief.Health
Primary Aldosteronism Evidence Reshapes Care Pathways
Updated evidence reinforces primary aldosteronism as a treatable cause of hypertension, supporting targeted evaluation, subtype classification, and…
- TheBrief.Health
WHO Updates COVID-19 Vaccine Priorities and Schedules
WHO’s 2026 COVID-19 guidance simplifies initial vaccination and prioritizes risk-based revaccination, emphasizing vulnerable groups, updated vaccines, and…
- TheBrief.Health
Zanidatamab Expands First-Line HER2-Positive GI Care
FDA authorized two zanidatamab-based first-line strategies with chemotherapy, with or without tislelizumab, for HER2-positive upper gastrointestinal…
- TheBrief.Health
Deramiocel for Duchenne Muscular Dystrophy: FDA Review Raises Questions About Cardiac Benefit
FDA advisers reviewed deramiocel’s cardiac evidence in Duchenne muscular dystrophy, weighing potential preservation of heart function against uncertain…
- TheBrief.Health
Myeloma Survival Unchanged With Longer Lenalidomide
ENDURANCE found no seven-year survival benefit from indefinite lenalidomide maintenance, supporting fixed two-year therapy as an evidence-based option for…
- TheBrief.Health
WHO Dementia Risk Guidance Needs Source Verification
A 2026 WHO media briefing does not verify revised dementia guidance, underscoring reliance on established recommendations until accessible evidence tables and…
- TheBrief.Health
Orlistat Kidney-Injury Warning Now Covers OTC Alli
FDA revised OTC orlistat labeling to warn about rare acute kidney injury, urging symptom awareness, prompt discontinuation, medical evaluation, and careful…
- TheBrief.Health
Tocilizumab Recall Demands Rapid Inventory Controls
FDA recalls one lot of IV tocilizumab-aazg over potential glass contamination, prompting immediate quarantine, inventory tracing, exposure review, and patient…
- TheBrief.Health
Advanced CKD: Rivaroxaban Adds Bleeding, Not Benefit
TRACK found that low-dose rivaroxaban failed to reduce cardiovascular events while increasing major bleeding in advanced CKD, arguing against routine…
- TheBrief.Health
PD-L1 Testing Defines New First-Line Option in TNBC
FDA approved sacituzumab govitecan plus pembrolizumab for first-line PD-L1 CPS ≥10 triple-negative breast cancer, expanding treatment options based on…
- TheBrief.Health
Selpercatinib Expands RET Fusion Testing Across Tumors
FDA’s traditional approval of selpercatinib expands tumor-agnostic treatment for RET fusion-positive solid tumors, covering eligible adults and children aged…
- TheBrief.Health
Daraxonrasib Challenges Second-Line Pancreatic Cancer Care
Daraxonrasib showed promising survival in KRAS-mutant metastatic pancreatic cancer, but stronger randomized evidence is needed before replacing standard…
- TheBrief.Health
Six-Month Strategy Holds Up in Rifampicin-Resistant TB
A randomized South African trial supports six-month treatment for eligible rifampicin-resistant tuberculosis, potentially reducing treatment burden while…
- TheBrief.Health
CKM Syndrome Guideline Standardizes Integrated Detection
The 2026 multisociety CKM guideline promotes integrated cardiovascular, kidney, and metabolic assessment, enabling earlier risk detection, coordinated care…
- TheBrief.Health
Extended DAPT Results Need Verification After Multivessel PCI
Extended DAPT after multivessel PCI remains individualized, as DAPT-MVD numerical efficacy and bleeding results require verification before influencing…
- TheBrief.Health
Finerenone Shows Cardiovascular and Kidney Benefits Across CKM Stages in Type 2 Diabetes and CKD
Finerenone reduced cardiovascular and kidney events across CKM stages in adults with diabetes and CKD, supporting broader risk assessment alongside…
- TheBrief.Health
SGLT Inhibitors in Heart Failure: Benefits Across Diabetes Status and Ejection Fraction
SGLT inhibitors reduce heart failure hospitalizations across ejection fractions and diabetes status, offering broad cardiovascular benefits while producing…
- TheBrief.Health
WHO Introduces Standardized Language for Hypertension Control Programs
WHO introduced standardized terminology for hypertension-control programs, creating shared definitions that improve care pathways, reporting, data alignment…
- TheBrief.Health
WHO Revises Pediatric HIV Antiretroviral Dosing
WHO’s July 2026 HIV update revises pediatric antiretroviral weight-band dosing and preferred regimens, emphasizing neonatal prophylaxis, formulation, growth…
- TheBrief.Health
Pluvicto Moves Earlier in PSMA-Positive Prostate Cancer
FDA approval expands Pluvicto into PSMA-positive metastatic hormone-sensitive prostate cancer, enabling earlier radioligand therapy alongside ARPI treatment…
- TheBrief.Health
COVID-19 Device EUA Exit Reshapes US Procurement
The FDA ended emergency authorizations for COVID-19 diagnostics and devices, requiring health systems to verify each product’s current regulatory status before…
- TheBrief.Health
Perioperative Pembrolizumab Expands in Bladder Cancer
FDA expanded perioperative enfortumab vedotin plus pembrolizumab to cystectomy-eligible muscle-invasive bladder cancer, regardless of cisplatin eligibility…
- TheBrief.Health
CKM Guideline Sets Staged Risk and Atherogenic Goals
The 2026 guideline integrates lipid care with CKM staging, PREVENT-ASCVD risk assessment, explicit LDL-C goals, optional apoB testing, and one-time Lp(a)…
- TheBrief.Health
Hypertension Treatment Thresholds Across Risk Groups
The 2026 guideline retains 130/80 mm Hg as hypertension’s threshold, while cardiovascular risk determines medication timing, with most treated adults targeting…
- TheBrief.Health
Bladder Cancer Outcomes Favor Enfortumab–Pembrolizumab
Perioperative enfortumab vedotin plus pembrolizumab improved survival and complete response rates versus cisplatin chemotherapy in resectable muscle-invasive…
- TheBrief.Health
Cyclosporiasis Outbreak Sharpens Need for Targeted Testing
During the 2026 Cyclospora outbreak, persistent watery diarrhea warrants targeted testing, as routine stool studies may miss infection even without…
- TheBrief.Health
Ensartinib Lowers Recurrence Risk in ALK-Positive NSCLC
Daily ensartinib significantly prolonged disease-free survival after chemotherapy and complete resection of ALK-positive NSCLC, supporting biomarker-guided…
- TheBrief.Health
Morphine Recall Raises Fatal Hydromorphone Substitution Risk
Fresenius Kabi recalled one morphine injection lot potentially containing hydromorphone, highlighting risks of opioid substitution, barcode failures…
- TheBrief.Health
Heart Failure Diagnosis Under the Second Universal Definition
The Second Universal Definition requires compatible symptoms, cardiac abnormalities, and objective evidence supporting heart failure, emphasizing integrated…
- TheBrief.Health
Teplizumab Expands to Pediatric Stage 3 Type 1 Diabetes
FDA expanded teplizumab to ages 8–17 with newly diagnosed stage 3 type 1 diabetes, preserving insulin-producing beta-cell function when treatment begins within…
- TheBrief.Health
Enlicitide Adds an Oral Option for Hypercholesterolemia
Enlicitide is the first oral PCSK9 inhibitor approved for additional LDL-C lowering, offering a convenient option for adults with persistent…
- TheBrief.Health
Imaging May Extend Stroke Thrombolysis to 24 Hours
Advanced imaging may identify salvageable brain tissue for selected stroke patients receiving IV thrombolysis up to 24 hours after onset, despite increased…
- TheBrief.Health
Atrial Fibrillation After PCI May Need 1-Month P2Y12
OPTIMA-AF supports stopping P2Y12 therapy after one month in selected AF patients undergoing PCI, reducing clinically important bleeding while maintaining…
- TheBrief.Health
FDA Approves Tirzepatide for Obstructive Sleep Apnea
Tirzepatide significantly reduced obstructive sleep apnea severity and body weight in adults with obesity, supporting FDA-approved treatment alongside…
- TheBrief.Health
Semaglutide Improves Kidney Outcomes in Type 2 Diabetes
FLOW demonstrated that semaglutide reduced kidney and cardiovascular risks in high-risk adults with type 2 diabetes and albuminuric CKD, supporting broader…
- TheBrief.Health
Decoding Rome V: Key Updates in Adult and Pediatric Gut-Brain Interaction Disorders
Rome V modernizes DGBI diagnosis with refined symptom scales, visual tools, expanded disorders, and pediatric severity assessment, improving precision…
- TheBrief.Health
Earlier Intervention May Improve Aortic Regurgitation Outcomes
Early intervention for severe aortic regurgitation may preserve heart function by treating asymptomatic patients before irreversible ventricular damage…
- TheBrief.Health
Sirolimus Conversion Improves Survival After Heart Transplant
Sirolimus conversion offers selected heart transplant recipients potential long-term benefits, slowing cardiac allograft vasculopathy, preserving kidney…
- TheBrief.Health
Comparative Effectiveness & Safety of LAMA-LABA Inhalers in COPD
A practical overview of COPD dual bronchodilator therapy, comparing LAMA–LABA inhalers by effectiveness, dosing, device usability, cost, patient needs, and…
- TheBrief.Health
The Algorithm & TikTok Triage: What KFF’s Health Information Poll Means for Clinical Practice
As patients increasingly use AI and social media for health advice, clinicians must address misinformation, delayed care, self-treatment, and digital trust.
- TheBrief.Health
Uncovering the Early-Life Roots of Early-Onset Colorectal Cancer
Early-onset colorectal cancer is rising among younger adults, with early-life exposures, birth characteristics, and demographics potentially influencing risk…
- TheBrief.Health
GLP-1 Receptor Agonists and the Reduction of Alcohol-Related Hospitalizations in Alcohol Use Disorder
New real-world evidence suggests semaglutide and tirzepatide may reduce alcohol-related hospitalizations among patients with AUD and metabolic disease…
- TheBrief.Health
Compounded Wellness Peptides Under Scrutiny: tECRI and ISMP Safety Warning
FDA’s 2026 regulatory shift on compounded peptides highlights major evidence gaps, manufacturing risks, and safety concerns, requiring clinicians to counsel…
- TheBrief.Health
Hidden Arboviral Threat: The Oropouche Virus
Oropouche virus is re-emerging as a global health threat, with expanding transmission, severe neurological and pregnancy complications, diagnostic challenges…
- TheBrief.Health
Monoclonal Antibodies for Hyperlipidemia: How PCSK9 Inhibitors Lower LDL Cholesterol
PCSK-9 monoclonal antibodies provide powerful LDL reduction and cardiovascular protection for high-risk patients, expanding treatment options beyond statins…
- TheBrief.Health
Parental Stress Is a Public Health Issue: Why It Matters
Parental stress is now recognized as a public health concern, highlighting its effects on family well-being and the need for stronger healthcare, workplace…
- TheBrief.Health
A New Frontier in ADHD Pharmacotherapy: Centanafadine (SIMTRIYO®)
The FDA has approved SIMTRIYO®, or centanafadine, for treating ADHD in adults and children six years and older. This is a significant development, as…
- TheBrief.Health
Drug-Related IE Now Majority Of Valve Surgeries In Some US Areas
Drug-related infective endocarditis is driving rising valve surgeries, highlighting the need for integrated cardiac, infectious disease, addiction…
- TheBrief.Health
What the FDA Approval and Phase 3 Data for Enlicitide Means for Preventive Cardiology
FDA-approved oral PCSK9 inhibitor enlicitide offers once-daily LDL-C lowering, potentially expanding treatment options for high-risk patients unable or…
- TheBrief.Health
Comparative Modeling Reveals Steep Upward Trajectories in Uterine Cancer Through 2050
NCI modeling projects rising uterine cancer incidence and mortality through 2050, with widening racial disparities highlighting urgent needs for prevention…
- TheBrief.Health
CYP2C19 Genetic Testing After PCI: A Promising Tool That Still Raises Practical Questions
CYP2C19 genotyping may personalize antiplatelet therapy after PCI, identifying patients at risk for reduced clopidogrel response while supporting more targeted…
- TheBrief.Health
Penumbra Enrolls 1st Pt In Distal Acute Stroke Thrombectomy Study
Emerging thrombectomy technologies aim to safely treat distal stroke occlusions, with the FORWARD trial evaluating whether advanced devices improve outcomes in…
- TheBrief.Health
Penumbra Enrolls 1st Pt In Distal Acute Stroke Thrombectomy Study
The FORWARD trial evaluates mechanical thrombectomy for distal stroke, exploring whether new aspiration technologies can safely expand treatment and improve…
- TheBrief.Health
The Discovery of GPR15-Guided CD8+TIGR Cells and Their Role in Inflammatory Bowel Disease
A landmark Nature study identifies regulatory CD8+TIGR cells that protect the gut, revealing new diagnostic biomarkers and targeted therapeutic opportunities…
- TheBrief.Health
Nyra Enrolls 1st Patient In Early Mitral Valve Feasibility Study
Nyra Medical’s first-in-human CARLEN study evaluates a novel transcatheter mitral leaflet implant, exploring less invasive repair for functional mitral…
- TheBrief.Health
Navigating the IV Fluid Shortage in Labor and Delivery
IV fluid shortages are forcing maternity teams to conserve supplies, prioritize high-risk obstetric care, and adopt alternative hydration strategies while…